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ABSTRACT
Medulloblastoma, the most common malignant pediatric brain cancer, is uniquely sensitive to DNA
damage-inducing therapies, with conventional treatment resulting in an 80% 5-year survival rate. Researching
the apoptotic pathways that make treatment effective in some tumors and how those pathways contribute to
resistance in others may identify therapies that reduce the need for toxic radiation and chemotherapy. In
cerebellar development, physiologic Sonic Hedgehog (SHH) signaling drives proliferation of cerebellar granule
neuron progenitors (CGNPs). Similarly, pathologic SHH hyperactivation drives proliferation in SHH-subgroup
medulloblastoma, which makes up 30% of medulloblastoma cases. SHH signaling upregulates target genes in
part by preventing H3K27 trimethylation marks via the JMJD3/KDM6B demethylase complex. In differentiated
cerebellar neurons, where SHH signaling is low, the polycomb repressive complex 2 (PRC2) silences SHH target
genes by trimethylating H3K27 residues in regulatory regions.
Our data show that blocking the PRC2 through genetic deletion has varying effects in different contexts.
When the PRC2-component Eed is deleted in SHH-subtype medulloblastomas that form in mice engineered for
SHH hyperactivation, the tumors show initially slower growth compared to tumors in Eed-intact controls;
however, the mice have significantly poorer survival. Therefore, this study aims to understand the mechanisms
of initially reduced tumor growth and ultimately more rapid tumor progression. Our recent single cell gene
expression analysis showed that Eed deletion in CGNPs induced genes involved in muscle cell differentiation,
including myogenin and troponin. We will characterize Eed-deleted medulloblastoma using
fluorescence-activated cell sorting (FACS) as well as immunohistochemistry (IHC). The first aim of this study is
to elucidate how cell cycle dynamics are altered in Eed-deleted medulloblastomas. The second aim of the
study tests whether Eed deletion alters the levels of cell cycle markers, cell death, and aberrant expression of
muscular proteins in SHH-driven medulloblastoma. Our cell cycle studies show that Eed deletion slows tumor
growth in early development, but the tumor later develops EED independence, resulting in more rapid
progression and decreased survival. Additionally, our data show that Eed deletion alters the expression of




The regulation of apoptosis is vital for both normal brain growth and the response
of brain tumors to therapy.1 Excessive apoptosis of cerebellar granule neuron progenitors
(CGNPs) can result in cerebellar hypoplasia,2,3 and failure to induce apoptosis can lead to
medulloblastoma formation.4 Medulloblastoma, the most common malignant pediatric
brain cancer, occurs in a region of the brain called the cerebellum, which is responsible for
motor learning, maintaining a sense of body position and posture, retaining balance and
equilibrium, and other fine movement coordination (Figure 1). This form of cancer is
uniquely sensitive to DNA
damage-inducing treatments such as radiation (Figure 2).
Conventional treatment plans include a combination of
radiation, chemotherapy, and surgical resection, which
results in a 5-year survival rate of 80%.5 Although 80% of
patients are sensitive to radiation and chemotherapy,
treatment still fails 20% of patients. Moreover, the
treatment is highly toxic, causing long-lasting impacts on
young patients who are still developing. These impacts
include endocrine abnormalities, growth impairments,
hearing loss, and cognitive decline.6,7,8 Thus, it’s important
to research the apoptotic pathways that make treatment
effective in some patients but not in others. Understanding
how apoptosis is regulated during cerebellar development
and medulloblastoma in mice can provide valuable
information about possible new therapeutic targets for
medulloblastoma treatment in humans.4,5,9 Gaining a better
understanding of these mechanisms may lead to the
development of treatment options that efficiently disrupt normal functioning to induce apoptosis in tumors;
intervention at the molecular level can help
reduce the need for radiation and chemotherapy,
thus lowering the toxicity of treatment for
medulloblastoma.
SHH Signaling
In early cerebellar development, Sonic
Hedgehog (SHH) signaling drives the proliferation
of cerebellar granule neuron progenitors
(CGNPs). This proliferation is needed to form the
cerebellar granule neurons (CGNs), the largest
neuronal population in the human brain.10 The
proliferating CGNPs are localized in the external
3
granular layer (EGL) of the cerebellum; as these
proliferating CGNPs differentiate into CGNs, they migrate
towards the internal granular layer (IGL) of the cerebellum
(Figure 3). However, if SHH is hyperactivated, it can
promote the over-proliferation of CGNPs, which can
eventually lead to the development of SHH-subgroup
medulloblastoma.11 This is the most common type of
medulloblastoma, with approximately 30% of
medulloblastoma cases falling within this subgroup.
SHH signaling has been shown to regulate the
activity of the polycomb repressive complex 2 (PRC2), a
chromatin modifying complex, in CGNPs.12 When SHH
signaling is not active, the PRC2 complex interacts with the
regulatory regions of the SHH target genes and
trimethylates H3K27 residues in order to repress the expression of those genes. However, when SHH signaling
is present, it drives expression of target genes by displacing the PRC2 complex and removing H3K27
trimethylation marks via the JMJD3/KDM6B demethylase complex, which also recruits activating SET1/MLL
H3K4 methyltransferases to further enhance the expression of the target genes.12 Accordingly, proliferating
CGNPs localized in the EGL, which would have high levels of SHH, have been shown to have low H3K27
trimethylation levels due to the displacement of the PRC2 complex; on the other hand, differentiating CGNs,
which have low levels of SHH, accumulate higher levels of H3K27 trimethylation as the neurons migrate from
the EGL to the IGL because of the replacement of the PRC2 complex (Figure 4). Due to PRC2’s role in regulating
proliferation and differentiation of CGNPs, it could play a role in
either supporting or resisting the formation of medulloblastoma
tumors.13
Eed Deletion
Research from the Gershon lab shows that mitosis-inducing SHH
signaling plays a key role in regulating apoptosis in CGNPs and in
medulloblastoma,14 thereby making PRC2 a central target of
study. The PRC2 is composed of a number of proteins, two of the
key components being EZH2 and EED. EZH2 is the catalytic
subunit of PRC2 that trimethylates H3K27 residues. EED supports
the role of EZH2 by binding to trimethylated H3K27 residues to
enhance the suppression of those genes.15 Thus, research
projects in the Gershon lab focus on understanding the effects of
conditionally deleting Eed to better interrogate the role of PRC2
in cerebellar development and medulloblastoma.
To study how altering the epigenetic balance of SHH-driven
CGNPs affects apoptotic priming, Abigail Cleveland (a PhD
candidate in the Gershon lab) conditionally deleted Eed in CGNPs
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of mice. Her findings showed that conditional deletion of Eed causes CGNPs to undergo apoptosis (Figure 5),
disrupting cerebellar growth and leading to cerebellar hypoplasia (Figure 6). Additionally, through
immunohistochemical studies, Abigail found that Eed-deleted
cerebella have decreased proliferation (pRB+) at P7, but this
proliferation is prolonged into P20 through the presence of
the EGL. In wildtype cerebella, by the time mice reach P14,
proliferation is completed and the EGL is eliminated.
Additionally she saw less differentiated (NeuN+) CGNs, and
increased expression of p21, a cell cycle inhibitor. More
surprisingly, single cell gene expression analysis showed that
Eed deletion in CGNPs caused the induction of genes involved
in muscle cell differentiation, including myogenin and
troponin.
When Eed was deleted in SHH
medulloblastomas, it resulted in smaller
tumors than Eed-intact controls (Figure 7);
however, the mice had significantly poorer
survival (Figure 8). Given these perplexing
outcomes, this study aims to better
characterize the role of Eed deletion in
medulloblastoma. The first aim of this study is
to elucidate how cell cycle dynamics are
altered in Eed-deleted medulloblastomas. The
second aim of the study tests whether Eed
deletion alters the levels of cell cycle markers,
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cell death, and aberrant expression of muscular proteins in SHH-driven medulloblastoma. The successful
completion of this project will inform future research regarding the role of EED in medulloblastoma. The hope
is that by better understanding the mechanisms through which Eed deletion induces spontaneous apoptosis
and possibly alters cell cycle dynamics of CGNPs, researchers could use that knowledge to develop more
effective therapeutic options to treat medulloblastoma tumors in patients.
METHODS
Breeding
To model SHH-subtype medulloblastoma in mice, we bred Math1-Cre mice, which express Cre
recombinase in the Math1+ CGNP population, with mice expressing a constitutively-active mutant
smoothened allele (SmoM2). The resulting M1cre; SmoM2 (MSmo) mice develop SHH medulloblastoma
tumors by 14 days old. We also bred the MSmo line with EedloxP/loxP mice. This generated Math1-Cre;
SmoM2;EedloxP/loxP (Eed cKO MSmo) mice in which Eed is deleted in the CGNP population.
Age Points
Eed cKO MSmo and control MSmo tumors were collected at postnatal day 12 (P12) for
immunohistochemical studies. Additionally, to assess how EED deletion impacts the cell cycle dynamics of
tumors over the course of time, mice were collected at both P12 and at
P18, the age at which approximately 50% of the Eed cKO MSmo mice
survived.
Fluorescence-Activated Cell Sorting (FACS)
Tumor cells from harvested medulloblastomas were dissociated
from 6 Eed cKO MSmo and 5 control MSmo mice at P12 as well as from
3 Eed cKO MSmo and 4 control MSmo mice at P18. Mice were first
injected with EdU 1 hour prior to harvest to label cells in S phase. To
determine whether Eed cKO MSmo tumors have different cell cycle
dynamics, the dissociated cells were stained for cell cycle markers
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5-ethynyl-2´-deoxyuridine (EdU), pRB, and FX cycle violet (DNA content marker) before performing
fluorescence-activated cell sorting (FACS). The results from FACS were analyzed using FlowJo software (Table
1). First, certain gating logistics were applied to remove any unwanted debris and doublets, after which cells in
G0 were defined as pRB negative and cells in M phase as highly pRB positive. Of the remaining cells that were
positive for pRB, the ones that were also positive for EdU were classified as S phase cells. The remaining cells
that were positive for pRB and negative for EdU were divided into G1 and G2 based on their DNA content: cells
with 2n DNA were in G1, and cells with 4n were in G2 (Figure 9). Once these counts were recorded, the
percentage of cells in G0, G1, S, G2, and M phase out of the total number of
cells were calculated and also the percentage of cells in G1, S, G2, and M
phase out of the total number of pRB positive cells was calculated.
Immunohistochemistry (IHC)
Tumors were also harvested from Eed cKO MSmo mice and Eed-intact MSmo
controls for immunohistochemistry (IHC). The harvested tumors were then
stained with markers for cell cycling, cell death, and muscle proteins, after
which the images were annotated to define the whole tumor. For myogenin,
a region high in tissue density (region of interest) was also annotated (Figure
10). Each of the stains in the images were quantified for the annotated
regions.
Statistical Analyses
Data from FACS cell cycle studies were analyzed using two statistical procedures. In order to assess
whether proliferation significantly differed both between genotypes (Eed cKO MSmo and control MSmo) and
ages (P12 and P18), unpaired two-tailed t-tests were performed. However, when comparing the distribution
across several cell cycle phases simultaneously, t-tests cannot be used because each of the phases must be
analyzed as a single collective vector rather than treating each phase independent of the other phases.
Instead, Dirichlet regressions were performed to compare the distribution of proliferating cells in different cell
cycle phases (G1, S, G2, and M) between genotypes (Eed cKO MSmo and control MSmo) and ages (P12 and
P18). All FACS data was analyzed using R x64 4.0.2. To analyze significance in the IHC data, unpaired two-tailed
t-tests were conducted between the Eed cKO and control MSmo mice. All IHC data was analyzed using
GraphPad Prism 9.
RESULTS
Fluorescence Activated Cell-Sorting (FACS)
To understand how EED deletion impacts cell cycle dynamics, the percentage of proliferating cells were
measured in Eed cKO MSmo and control MSmo samples after which the proliferating cells were gated into
more specific cell cycle phases. At P12, there were less proliferating cells in Eed cKO MSmo tumors than in
MSmo control tumors (Figure 11A), but this difference between genotypes was eliminated by the time mice
reached P18 (Figure 11B). At both age points, the distribution of proliferating cells across the four cell cycle
phases were statistically different between the two genotypes; more specifically, there was an increased
proportion of proliferating cells in S phase in the Eed cKO MSmo mice (Figure 11C-D). When doing cross-age
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comparisons, there is a significant increase in the number of proliferating cells from P12 to P18 in Eed cKO
MSmo mice (p < 0.001). However, no such statistical difference is seen in control MSmo mice. Similarly, the
distribution of proliferating cells across the four cell cycle phases is statistically different at P12 and P18 in Eed
cKO MSmo mice; specifically, there was a decrease in the proportion of mitotic cells at P18 (p < 0.05). However,
no statistical difference in the distribution of proliferating cells among cell cycle phases existed in control
MSmo mice between P12 and P18.
Immunohistochemistry (IHC)
IHC analysis was used to determine whether EED alters cell cycling and differentiating markers in MSmo
tumors. Eed deletion significantly reduced both proliferation (pRB+; Figure 12A) and neural differentiation
(NeuN+; Figure 12B) in Eed cKO MSmo tumors compared to control MSmo tumors, but we found no significant
differences when comparing expressions of p21 (Figure 12C) or Cdkn1C (Figure 12D).
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Compared to control MSmo tumors, Eed cKO MSmo had significantly less independent expression of
apoptosis (Figure 13A) and DNA damage (Figure 13B) as well as less co-expression of the two (Figure 13C).
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Eed cKO MSmo tumors showed significantly more myogenin expression compared to control MSmo
tumors (Figure 14A). The increased expression of myogenin was not only seen across the whole tumor, but
also in the hypercellular tumor-dense region. We did not, however, detect an increase in troponin (TNNT3;
Figure 14B), as we previously saw in the Eed-deleted cerebellum.
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DISCUSSION
Both fluorescence-activated cell sorting (FACS) and immunohistochemistry (IHC) data showed a
decreased proportion of proliferating cells in Eed cKO MSmo tumors compared to control MSmo tumors at
P12, indicating that there are more cells exiting the cell cycle at that point in time when EED is not present.
However, FACS studies showed that at P12, Eed cKO MSmo tumors have an increased proportion of
proliferating cells in S phase; and that Eed cKO MSmo tumors at P12 have a greater proportion of proliferating
cells in M phase compared to Eed cKO tumors at P18. Collectively, these data points lead to the conclusion that
although there are more cells exiting the cell cycle at P12 in Eed cKO MSmo tumors, of the ones that remain,
they are cycling faster than in control MSmo tumors.
By the time the mice reach P18, FACS data shows that some of these changes are compensated so that
the cell cycle dynamics of the Eed cKO tumors are not as different from control MSmo tumors. There is a
significant increase in the proportion of proliferating cells in Eed cKO tumors from P12 to P18 so that Eed cKO
tumors no longer differ in that regard from control MSmo tumors. However, even at P18, there continues to be
a greater proportion of proliferating cells in S phase, indicating that proliferating cells are still cycling faster in
Eed cKO MSmo tumors than in control MSmo tumors. Thus, based on the cell cycle studies conducted here,
Eed deletion slows tumor growth in early development, but the tumor later develops resistance, resulting in
decreased survival.
Overall, at P12, through IHC data, Eed-deleted tumors showed reduced proliferation (decreased pRB),
reduced neural differentiation (decreased NeuN), reduced apoptosis (decreased cC3), and aberrant muscle
differentiation (Myog). While preliminary studies also showed decreased differentiation and proliferation in
Eed-deleted CGNPs, an opposite phenotype was observed in regards to apoptosis. Additionally, Eed cKO MSmo
tumors had equivalent amounts of p21 compared to MSmo tumors while Eed-deleted CGNPs had increased
p21 expression. In cerebellar CGNPs, Eed deletion invokes increased expression of both myogenin and troponin
(TNNT3); however, when deleting Eed in MSmo tumors, it only causes increased aberrant expression of
myogenin, not troponin. The lack of increased troponin expression suggests that in tumors, unlike Eed-deleted
cerebella, later stages of muscle differentiation were blocked. Since both proliferation and neural
differentiation were reduced, muscle differentiation may have been an alternative fate for tumor cells exiting
the cell cycle, and pRB studies in the MYOG+ population are needed to test the possibility.
Although the experiments
presented here help better characterize
the impacts of deleting EED in
medulloblastoma tumors, a more
thorough understanding of needs to be
developed before EED or other members
of the PRC2 can be implicated in
molecular therapies. EED is predominantly
found in PRC2 but also in PRC1, and these
interact with other complexes like
SET1/MLL and JMJD3 to regulate SHH-target gene expression. Thus, EED interacts with various epigenetic
complexes through which Eed deletion can potentially invoke the observed phenotypes. As an extension of this
project, one could better define exactly which complexes might contribute toward this phenotype by
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measuring the levels of specific histone modifications. This would entail collecting tumor lysates and
performing western blots for various histone markers such as H3K27me3 (associated with PRC2 and JMJD3),
H2AK119 (associated with PRC1), and H3K4me3 (associated with SET1/MLL) (Figure 15). Identifying which
changes in histone modifications correlate with Eed deletion will better elucidate what mechanisms and
complexes, with which EED associates, are responsible for driving these phenotypes. By understanding how
SHH signaling regulates target gene expression and the mechanisms of Eed deletion in medulloblastoma
mouse models, researchers may be able to develop novel therapeutics for SHH-driven medulloblastoma.
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